Atalanta Therapeutics, Inc. is an American company located in Boston, MA, that develops RNA interference based therapeutics to treat neurodegenerative diseases. It was founded by Neil Aronin, Craig C. Mello, Anastasia Khvorova and Jim Glasheen. Alicia Secor is currently the CEO of the firm.\nThe company says this about itself: Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform, branched siRNA, which for the first time enables RNA interference to be deployed as a therapeutic approach throughout the brain and spinal cord. Atalanta was founded in 2018 by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital and strategic collaborations with Biogen and Genentech. Atalanta is headquartered in Boston, Mass.